<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327521</url>
  </required_header>
  <id_info>
    <org_study_id>HEP0030</org_study_id>
    <secondary_id>ACCH001.0</secondary_id>
    <secondary_id>SU-05052010-5862</secondary_id>
    <nct_id>NCT01327521</nct_id>
  </id_info>
  <brief_title>Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma</brief_title>
  <official_title>International Randomized Study of Transarterial Chemoembolization Versus CyberKnife for Recurrent Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Koong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Accuray Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC
      after initial TACE.

      Secondary Objectives:

        1. To determine the progression-free survival of TACE vs. CyberKnife SBRT

        2. To determine the overall survival of TACE vs. CyberKnife SBRT for locally recurrent HCC

        3. To determine the toxicities associated with TACE or CyberKnife SBRT for the treatment of
           recurrent HCC.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Accrual below target levels
  </why_stopped>
  <start_date>February 2011</start_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from local progression at 6 months and 12 months</measure>
    <time_frame>6 months and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 6, 12 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 6, 12, 18 months and up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum AFP levels</measure>
    <time_frame>1 month, 3 months, 6 months, 12 months and 18 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CyberKnife</intervention_name>
    <description>Standard of Care</description>
    <other_name>CK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Standard of Care</description>
    <other_name>Transcatheter arterial chemoembolization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT Contrast</intervention_name>
    <description>Standard of Care</description>
    <other_name>contrast dye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>Standard of Care</description>
    <other_name>Adriamycin</other_name>
    <other_name>hydroxydaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Standard of Care</description>
    <other_name>Ellence</other_name>
    <other_name>Pharmorubicin</other_name>
    <other_name>Epirubicin Ebewe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>Standard of Care</description>
    <other_name>5-FU</other_name>
    <other_name>f5U</other_name>
    <other_name>Adrucil</other_name>
    <other_name>Carac</other_name>
    <other_name>Efudix</other_name>
    <other_name>Efudex</other_name>
    <other_name>Fluoroplex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Standard of Care</description>
    <other_name>Mutamycin</other_name>
    <other_name>MTC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Standard of Care</description>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Standard of Care</description>
    <other_name>cisplatinum</other_name>
    <other_name>cis-diamminedichloroplatinum(II)</other_name>
    <other_name>CDDP</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SMANCS</intervention_name>
    <description>Standard of Care</description>
    <other_name>styrene maleic acid neocarzinostatin</other_name>
    <other_name>poppyseed oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed hepatocellular carcinoma by one of the following:

               -  Histopathology

               -  One radiographic technique that confirms a lesion &gt;=2 cm with arterial
                  enhancement with washout on delayed phase

          -  Hepatic lesion in patients for whom surgical resection is not possible or would not
             result in an opportunity for cure

          -  Radiographic evidence of persistent, progressive or recurrent disease in an area
             previously treated with TACE. This evaluation should be determined after 6 weeks of
             initial TACE

          -  Multi-specialty evaluation whereby the recurrent liver lesion was deemed by both the
             attending radiation oncologist and interventional radiologist amenable to treatment by
             the respective modality

               -  Eligible patients must undergo an IV contrast CT scan of the liver within 6 weeks
                  of enrollment onto the study; a contrast enhanced liver MRI may be substituted
                  for the IV contrast CT of the liver.

               -  A recent serum AFP must also be obtained within 4 weeks of enrollment.

          -  Unifocal liver tumors not to exceed 7.5 cm in greatest axial dimension. Multifocal
             lesions will be restricted to lesions that can be treated within a single target
             volume within the same liver segment and to an aggregate of 7.5cm as long as the dose
             constraints to normal tissue can be met

          -  Eastern Clinical Oncology Group performance status 0, 1 or 2

          -  Patients with liver disease classified as Child Pugh class A/B; if Child's class B,
             score must be 8 or less

          -  Albumin &gt;= 2.5 g/dL

          -  Total bilirubin &lt;= 3 mg/dL

          -  INR &lt;= 1.5

          -  Creatinine &lt;= 2.0 mg/dL

          -  Age &gt;= 18 years old

          -  Life expectancy&gt;= 6 months

          -  Ability of the research subject or authorized legal representative to understand and
             the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Prior radiation for the recurrent liver tumors

          -  Prior radiotherapy to the upper abdomen

          -  Prior RFA to index lesion

          -  Liver transplant

          -  Tumors &gt;= 7.5 cm in greatest axial dimension

          -  Portal vein thrombus

          -  Large varices within 2 cm of index lesion (seen on cross section imaging)

          -  Contraindication to receiving radiotherapy

          -  Active gastrointestinal bleed within 2 weeks of study enrollment

          -  Ascites refractory to medical therapy

          -  Women who are pregnant

          -  Administration of any systemic chemotherapy within the last 1 month

          -  Presence of multifocal lesions located in different lobes of the liver or extrahepatic
             metastases

          -  Participation in another concurrent SYSTEMIC treatment protocol

          -  Prior history of malignancy other than HCC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Koong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>March 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Albert Koong</investigator_full_name>
    <investigator_title>Associate Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

